CDK4 and neoplasm: CDK4/6 inhibitors (CDK4/6i) showed effectiveness against glioblastoma, breast cancer and melanoma by arresting tumor cell cycle at G1, via inhibition of retinoblastoma tumor suppressor phosphorylation (126).